High blood pressure is an established risk factor for the development of dementia [1] . Results The aim of this study was to compare differences in brain atrophy and cognitive decline between 8 people taking ACEi and ARB using data from a community-dwelling sample of older people 9 enriched with type 2 diabetes (T2D), as RAS agents are more commonly used in T2D.
10

MATERIALS AND METHODS
11
Study population 12 The sample was derived from two prospective cohort studies conducted concurrently within the made by a physician using standard criteria (fasting plasma glucose ≥ 7.0 mmol/L, random 21 plasma glucose ≥ 11.1 mmol/L, or 2-h glucose ≥ 11.1 mmol/L after oral glucose tolerance test).
The same definition was applied to TASCOG participants to confirm or exclude T2D status.
1
Exclusion criteria were identical for both studies -being resident in a nursing home, insufficient 2 English for cognitive testing or any contraindication to MRI scan. Both groups were followed up 
Measurements
10
All study measurements used in this analysis were collected in both cohorts using the same 11 techniques and tools. individual test we standardised scores at each visit by creating z scores using the mean and SD 11 from the baseline visit. These domain scores were also averaged to create a global cognitive 12 score and the average scores for each of the 7 listed cognitive domains. Domain scores with 13 more than one cognitive test were re-standardized to a SD of 1. Similar to previous work [19, 25], the re-standardized scores were used in the regression analysis to allow comparison of 15 associations across cognitive domains.
16
MRI Brain (total brain and lateral ventricular volume)
17
Brain MRI prior to January 2011 was performed using a 1.5-Tesla scanner (LX Horizon, General broadly similar ( Table 2) .
21
Comparison of ACEi and ARB use
A total of 163 people were taking an ACEi and 125 were taking an ARB on study entry. A total 1 of 11 people were taking both ACEi and ARB and were excluded from analysis. The baseline 2 characteristics of those taking either an ACEi or ARB were similar with regards to age, sex, 3 blood pressure control and vascular risk factors and are described in detail in Table 1 and across 4 time points in Table 2 . Although those taking an ARB had lower baseline volume of white 5 matter hyperintensities, and lower prevalence of brain infarct or microbleeds, these differences (Table 3 ). There was an interaction between AHM use and time on verbal fluency scores, 9 whereby those on AHM had a greater rate of decline in verbal fluency than those not on AHM
10
(β=-0.05, p=0.007).
11
Monotherapy
12
Of those taking BP lowering medications, a total of 166 were taking a single medication (64 on
13
ACEi, 45 on ARB, 24 on β-blocker, 18 on Calcium Channel Blocker (CCB), and 15 on diuretic). 
10
Although we report brain structural differences between groups, we did not find consistent 11 cognitive differences. This lack of correlation between cognitive and brain structural measures 
5
This study has a number of limitations. We followed people for a relatively short period of time 6
and it may be that larger signals would be identified in cognition and brain structure over a (83) n (%) n (%) n (%) n (%) n (%) n (%) Female sex 84 (42) 12 ( 
